natgillin/translations-raw huggingface dataset:
The use of such antibiotics within nasal treatments is widely reported in the literature as will be readily recognized by the skilled artisan, however no such nasal treatment is reported in conjunction with the intranasal application of therapeutic cells and/or pharmaceutical compositions comprising therapeutic cells to the upper third of the nasal cavity whereby the blood-brain barrier is bypassed. Immunosuppressive Agents 
Terapijske stanice namijenjene upotrebi u skladu s patentnim zahtjevom 1, naznačene time što se navedeno liječenje dodatno sastoji u primjeni terapijskih stanica u tkivo inervirano njušnim živcem, gdje najmanje jedna terapijska stanica zaobilazi krvno-moždanu barijeru kako bi dospijela u oštećeni središnji Živčani sustav; i minimaliziranju sistemskog unosa terapijskih stanica izvan središnjog živčanog sustava.
130 g/l or 135 g/l, to which at least a sugar and a surfactant have been added then the method is operated in an embodiment with an applied pressure of 0.7 bar or less. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da otopina imunoglobulina sadrži šećer 1 tenzid i ima koncentraciju od 125 mg/ml ili više, te se nanošenje na kombinaciju filtera vrši primjenom tlaka od 0,75 bara ili manje.
A method of reducing B cell tumor volume in a subject in need thereof, the method comprising administering an effective amount of a humanized or chimeric CD37-specific binding molecule derived from G28-1 and comprising a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 64; a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 66; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 63; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 65; and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 67 or 68; 
humane okvirne regije lakog lanca, laki lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:61, laki lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:64 i laki lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO:66, i humane okvirne regije teškog lanca, teški lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:63, teški lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:65 i teški lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO: 67 ili 68.
A compound of the formula: or a salt or solvate thereof. 
Spoj formule [50], ili njegova sol ili solvat
In like manner to that described in Example 2 the named compound was prepared by using L-(+)-mandelic acid in place of D-(-)-mandelic acid as the selective precipitant [m.p. 
Na sličan način s onim kao što je opisano u primjeru 2 napravi se imenovani spoj korištenjem L-(+)-bademove kiseline umjesto D-(-)-bademove kiseline kao selektivnog taložnog sredstva (tt.
The antibody or antigen binding portion thereof according to any one of claims 1 to 8 for use according to claim 18, wherein the cancer is pancreatic cancer, melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, clear cell sarcoma, or prostate cancer. 
Izolirano monoklonsko antitijelo ili njegov dio koji se vezuje za antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 7 ili pripravak u skladu s patentnim zahtjevom 8 za uporabu u postupku liječenja karcinoma, pri čemu je karcinom izborno odabran od melanoma, karcinoma dojke, karcinoma jajnika, karcinoma bubrega, gastrointestinalnog karcinoma/karcinoma debelog crijeva, karcinoma pluća, sarkoma svijetlih stanica i karcinoma prostate.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 19, 22, 34, and 358, in which 1 or 2 amino acids are substituted, deleted, or added, wherein said peptide induces cytotoxic T lymphocytes specific to a cell expressing CDH3. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:376 i 379, u kojima su 1 ili 2 aminokiseline zamijenjene, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
dissolving the levothyroxine in the basic aqueous solvent to yield a levothyroxine solution, and 
otapanja levotiroksina u baznom vodenom otapalu, kako bi se dobila otopina levotiroksina, i
The aqueous phase was washed with methylene chloride (51), filtered clear (Celite®) and concentrated by evaporation under reduced pressure to about 21 total volume. 
Vodena faza je oprana s metilen kloridom (8 1) filtrirana bistro (Celit) i koncentrirana uparavanjem pod smanjenim tlakom do oko 2 1 ukupnog volumena.
The method of E 8, wherein the monoclonal antibody or monoclonal antibody fragment binds to and inhibits the activity of IL-17RA or IL-17RC. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 8, naznačen time, da se monoklonsko antitijelo ili fragment monoklonskog antitijela veže na i inhibira djelovanje IL-17RA ili IL-17RC.
An isolated or purified peptide of any one of Claims 1 to 3, or a pharmaceutical composition of Claim 6 for use in ameliorating or treating a Yc cytokine-mediated disease, wherein the Yc cytokine-mediated disease is selected from the group consisting of: CD4-leukemia, CD8-leukemia, LGL-leukemia, systemic lupus erythematosis, Sjoegren's syndrome, Wegener's granulomatosis, Celiac disease, Hashimoto's thyroiditis, rheumatoid arthritis, inflammatory bowel disease, diabetes mellitus, psoriasis, multiple sclerosis, uvietis, inflammation of the eye, and graft-versus-host disease (GvHD). 
Izolirani ili pročišćeni peptid prema bilo kojem od patentnih zahtjeva 1 do 3, ili farmaceutski pripravak prema patentnom zahtjevu 6, za uporabu u cilju ublažavanja ili liječenja bolesti posredovane Yc citokinom, naznačen time što je bolest posredovana Yc citokinom odabrana iz grupe koja se sastoji od: CD4-leukemije, CD8-leukemije, LGL-leukemije, sistemskog eritematoznog lupusa, Sjegrenovog sindroma, Vegenerove granulomatoze, celijakije, Hašimoto tireoiditisa, reumatoidnog artritisa, upalne bolesti crijeva, dijabetesa melitusa, psorijaze, multiple skleroze, uveitisa, zapaljenja oka i bolesti cijepiva protiv domaćina (GvHD).
The method of claim 8, wherein the progesterone is released from the intravaginal ring at about 10 mg/day to about 40 mg/day in vivo, or wherein the progesterone is released from the intravaginal ring at about 10 mg/day to about 30 mg/day in vivo, or wherein the progesterone is released from the intravaginal ring at about 15 mg/day to about 25 mg/day in vivo. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 7, naznačen time, da se iz intravaginalnog prstena otpušta od 10 mg/dan do 40 mg/dan progesterona in vivo, ili pri čemu se iz intravaginalnog prstena otpušta od 10 mg/dan do 30 mg/dan progesterona in vivo ili pri čemu se iz intravaginalnog prstena otpušta od 15 mg/dan do 25 mg/dan progesterona in vivo.
The composition according to any one of claims 1-4, wherein said lecithin is a lecithin E322 and is selected from the group comprising the maize, sunflower or soya lecithin; said lecithin is in an amount comprised from 0.1 to 1.5, preferably from 0.4 to 1% by weight. 
lecitina, koji je lecitin E322, gdje se navedeni lecitin bira iz skupine koju čine kukuruzni, suncokretov ili sojin lecitin; i u količini je koja se kreće od 0,1 do 1,5 %, težinski.
The marking device according to claim 1, wherein the chassis comprises a number of rolling elements. 
Uređaj sukladno zahtjevu 1, gdje šasija sadrži određeni broj rotirajućih elemenata.
An anti-FcRn antibody or binding fragment thereof according to claim 1, wherein the variable domain of the heavy chain comprises a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO: 25 and wherein the variable domain of the light chain comprises a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO: 16. 
Anti-FcRn antitijelo ili njegov vezujući fragment koji se sastoji od (i) teškog lanca ili fragmenta teškog lanca koji sadrži varijabilnu regiju koja se sastoji od sekvence navedene u SEQ ID NO:25 i (ii) lakog lanca ili fragmenta lakog lanca koji sadrži varijabilnu regiju koja se sastoji od sekvence navedene u SEQ ID NO: 16.
A is selected from the group consisting of R3 is hydrogen or methyl; and R4 is hydrogen, methyl, ethyl or isopropyl. 
A se bira iz skupine koju čine [image] [image] [image] je vodik ili metil; i je vodik, metil, etil ili izopropil.
is coupled to resilient means (35) naturally biased to drive said latch to its fixing position, 
spojen je s elastičnim sredstvima (35) koja su u osnovi nagnuta na način da vode navedeni zasun do fiksiranog položaja,
The arrangement according to claim 3, wherein the at least two devices are fastened to the half of the respective shaft bracket facing a propeller. 
Sustav u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je svaki od najmanje dva uređaja (20) pričvršćen na konzolu osovine (10).
keep the fish in the net cage (1) so that the fish may spontaneously swim up to the water surface (5) in the connection channel (6) and may spontaneously swim back down to the fish enclosure (3). 
Cc) - držanje ribe u mrežastom kavezu (1) tako da riba može spontano plivati sve do površine vode (5) u spojnom kanalu (6) i može se spontano spustiti natrag do ograde za ribu (3).
Examples of proteins having a HhH motif in their sequence are, but not limited to, the DNA topoisomerase V of Methanopyrus kandleri, the proteins MutY, Nth, MutM/Fpg, Nei, UvrC, DinP, RecR, UmuC, DnaE or DnIJ of Escherichia coli or the proteins RAD1, RAD2, RAD10, RAD27, RAD 55, RAD 57, REV1, OGG1, NTG1, NTG2, DIN-7 or EXO-1 of yeasts, as well as the homologs of these proteins in other organisms such as for example, but not limited to, Bacillus subtilis, Caenorhabditis elegans, Haemophilus influenzae, Methanococcus jannaschii, Micrococcus luteus, Methanobacterium thermoformicum or Salmonella typhimurium. 
DNK polimeraza himera prema zahtjevu 1, gdje lanac amino kiselina O sadrži najmanje jednu HhH domenu proteina koja je odabrana s popisa koji sadrži: topoizomeraze V od Methanopyrus kandleri, MutY, Nth, MutM/Fpg, Nei, UvrC, DinP, RecR, UmuC, DnaE or DniJ od Escherichia coli, RADI, RAD2, RAD10, RAD27, RAD 55, RAD 57, REVI, OGGI, NTGI1, NTG2, DIN-7 ili EXO-I od kvasca, ili homologni protein od gore navedenog u Bacillus subtilis, Caenorhabditis elegans, Haemophilus influenzae, Methanococcus jannaschii, Micrococcus luteus, Methano- bacterium thermoformicum or Salmonella typhimurium.
X, B, Ω, a, and b are as defined above; and each p is independently 0 or 1. 
X,B,%, aib jesu kao što je gore definirano, te p jest 0 ili 1.
The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. 
CHF2, OCHF2, OCHZE, O-fenil, fenil, NO2; kao i njihove fiziološki prihvatljive soli i tautomerni oblici.
The planar element according to claim 11, further comprising at least one printed image and inscription. The planar element according to claim 11, further comprising at least one illuminating element, in particular back-lighting, for example from the area or side of the planar element remote from the coating. 
Ravni element prema barem jednom od zahtjeva 1 do 5, naznačen time da ima barem jedan rasvjetni element (60), naročito pozadinsko osvjetljenje, na primjer na površini ili strani ravnog elementa (100) okrenutoj od premaza (30).
The method according to claim 16, wherein the oxygen content of the offgas after the contact with the catalyst is within the range of 3-10%. The method according to claim 16, wherein the oxygen content of the offgas after the contact with the catalyst is at least 4%. 
Uređaj u skladu s bilo kojim od zahtjeva 13-15, prilagođen tako da se kontakt s oksidacijskim katalizatorom kontrolira putem monitora kisika tako da se sadržaj kisika u oslobođenom plinu nakon kontakta s oksidacijskim katalizatorom kreće u rasponu od 3-10%.
Pharmaceutical composition comprising an anti-IL-1B antibody or fragment thereof, for use in the treatment of rheumatoid arthritis, wherein the antibody or antibody fragment binds to human IL-1B with a dissociation constant of 1 pM or less, wherein the antibody or fragment thereof competes with the binding of an antibody having the light chain variable region of SEQ ID NO: 5 and the heavy chain variable region of SEQ ID NO: 6, wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses, wherein the initial dose and each one or more subsequent doses are administered at an interval of once a week to once every six months and wherein the antibody or antibody fragment is to be administered at a dose of at least 0.01 mg/kg to 1 mg/kg of antibody or fragment thereof. 
Farmaceutska smjesa koja sadrži anti-IL-1B protutijelo ili njegov fragment, za uporabu u liječenju reumatoidnog artritisa, gdje se protutijelo ili fragment protutijela veže za humani IL-1B s konstantom disocijacije od 1 pM ili manje, gdje se protutijelo ili njegov fragment natječe s vezanjem protutijela koje kao varijabilnu regiju lakog lanca ima SEQ ID NO: 5 i kao varijabilnu regiju teškog lanca ima SEQ ID NO: 6, gdje nakon primjene inicijalne doze protutijela ili fragmenta protutijela slijedi primjena jedne ili više sljedećih doza, gdje se inicijalna doza i svaka ili sljedeća doza daju u razmaku od jednom tjedno to jednom svakih šest mjeseci i gdje se protutijelo ili fragment protutijela daju u dozi od barem 0.01 mg/kg do 1 mg/kg protutijela ili njegovog fragmenta.
The soft chewable veterinary composition of claim 1, wherein the compound of Formula (I) is present at a concentration of about 1% to about 5% by weight. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da je spoj formule (I) prisutan u koncentraciji od oko 1% do oko 5% po masi.
Once the pH is lowered from pH 7.2 to pH 4, the pyridine ring in the resin and the bound antibody become positively charged, due to charge repulsion, the immunoglobulins detaches and elutes from the column. 
Jednom kada sc pH spusti sa pH 7.2 na pH 4, piridinski prsten u smoli i vezano protutijelo postaju pozitivno nabijeni, te se zbog odbijanja istoimenih naboja imunoglobulin odvaja i eluira sa kolone.
The material was filtered, washed with 5 ml of methanol at −10 to −15° C., filtered and dried at 40-45° C. for 8 h to obtain 11.5 g of the title compound. 
Materijal je profiltriran, ispran s 5 ml metanola na -10 *C do -15 "C, profiltriran i osušen na 40-45 "C tijekom 8 sati da bi se dobilo 11,5 g spoja 1z naslova.
As illustrated in Figure 2 (Scheme 2), the same steps as above may be followed-absent the hydrazinolysis step-when the starting material is a 10-deacetyl taxane, such as of generalized Formula A' in Figure 2. 
Kao što je prikazano na slici 2 (shema 2), isti koraci kao i gore mogu slijediti -uz odsustvo koraka hidrazinolize - kada je početni materijal 10-deacetil taksan, kao npr. onaj opće formule A'na slici 2.
In JP 2000212483 a polyglycerin ester of fatty acids is added to an aqueous paint. 
U JP 2000212483 je u vodeni premaz dodan poliglicerinski ester masnih kiselina.
ppm polysorbate 80 in combination with 10 mM methionine or 80 ppm polysorbate 80 in combination with 5 mM methionine, mM sucrose, 
75 ppm polisorbata 80 u kombinaciji s 10 mM metioninom ili 80 ppm polisorbata 80 u kombinaciji s 5 mM metioninom, c.
Use according to any one of claims 1 to 5 wherein the salt is comprised in an amount of 20 to 500 mM, or in an amount of 30-300 mM or in an amount of 50-150 mM. 
Uporaba sukladno zahtjevu 1, pri čemu je sol sadržana u količini od 20 do 500 mM, ili u količini od 30-300 mM ili u količini 50-200 mM.
said antibody is a monoclonal antibody which has cytotoxicity against Lymphocyte antigen 75 expressing cells in the presence of human immune effector cells. 
(E) spomenuto antitijelo je monoklonalno antitijelo sposobno za specifično vezivanje na limfocitni antigen 75 1 koji ima citotoksičnost protiv stanica koje izražavaju limfocitni antigen 75 uz prisutnost ljudskih efektornih imunosnih stanica.
An antibody of any preceding claim for use in a method of treating a subject suffering from cancer, optionally wherein the cancer is breast, lung or prostate cancer. 
Antitijelo prema bilo kojem od Patentnih zahtjeva od 1 do 9 za upotrebu u postupku tretmana prema Patentnom zahtjevu 13, naznačenog time, što rak koji se tretira predstavlja kancer dojke, pluća ili prostate.
correlating the presence or absence of the immunological complex with the presence or absence of amyloid antigen in the sample; 
koreliranja prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog antigena u uzorku.
PRIOR ART Cyclic nucleotide phosphodiesterase (PDE) inhibitors (in particular of type 4) are currently of particular interest as a new generation of active ingredients for the treatment of inflammatory disorders, especially disorders of the respiratory tract such as asthma or airway obstructions (such as, for example, COPD=chronic obstructive pulmonary disease). 
Stanje tehnike Inhibitori cikličke nukleotid fosfodiesteraze (PDE) (tip 4) su u sadašnje vrijeme od posebnog interesa kao nova generacija aktivnih sastojaka za liječenje upalnih poremećaja, posebno poremećaja respiratornog trakta poput astme ili opstrukcije dišnih puteva (poput na primjer COPD = kronične opstruktivne plućne bolesti).
attenuates or blocks the ability of PD1 to bind to a PD1 ligand; 
(A) smanjuje sposobnost liganda PD-1 da veže na PD-1;
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, or a cell according to claim 6, in solution or in lyophilized form; and 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili 7 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku; te
Cytotoxic modular antibody with a molecular weight of up to 60kD, specifically binding to a cell surface target with a binding affinity of Kd <10-8 M, wherein the antibody contains a binding site for the cell surface target within a structural loop region of a CH3 domain of the antibody, and wherein the cell surface target is a receptor of the erbB class. 
Citotoksično modularno protutijelo, naznačeno time, da se specifično veže za cilj na površini stanice s afinitetom vezanja od Kd<10-8 M, pri čemu je to Fc (Fcab) koji veže antigen molekule protutijela s funkcijom efektora, koje ima barem jednu od ADCC, ADCP i CD aktivnosti, s mjestom vezanja antigena uređenim na području čvorova od domene CH3 za vezanje na spomenuti cilj na površini stanice, pri čemu cilj na površini stanice je receptor iz razreda erbB.
After this time, the reaction was poured into a 1:1 water: hexane mixture (2000mL). 
Nakon ovog vremena reakcijska smjesa je izlivena u smjesu voda: heksan, 1:1 (200 mL).
Use of a compound in the manufacture of a medicament for use in a method of treatment or prophylaxis of a tauopathy condition in a patient, or a disease of tau protein aggregation in a patient, wherein the compound is: 
Uporaba spoja diaminofenotiazinija, naznačena time, da je za proizvodnju lijeka koji se upotrebljava u postupku liječenja ili profilakse stanja taupatije kod pacijenta, pri čemu je taj spoj odabran od sljedećih:
A process for preparing a pharmaceutical composition containing a mixture of polypeptides which do not all have the same amino acid sequence, where each polypeptides consists essentially of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a predetermined percentage of brominated tyrosine acceptable for inclusion in a pharmaceutical composition; which comprises obtaining a batch of a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of glutamic acid, alanine, tyrosine and lysine; 
Smjesa prema patentnom zahtjevu 27, naznačena time, da je boja smjese manja od 500 APHA. Postupak za pripremu farmaceutskog sastava koji sadrži smjesu glatiramer acetata, naznačen time, da smjesa ima predodređeni postotak bromiranog tirozina, koji je postotak prihvatljiv za uključivanje u farmaceutski sastav, i koji postupak obuhvaća dobivanje šarže glatiramer acetata;
The process as defined in claim 4, wherein the compound of formula (I) is a sulfuric acid salt hydrate. 
Postupak kako je definirano u patentnom zahtjevu 5 ili zahtjevu 6, naznačen time što je spoj s formulom (I) hidrat soli sumporne kiseline.
A compound according to any one of the preceding claims, wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate. 
Spoj prema bilo kojem od prethodnih zahtjeva, gdje je farmaceutski prihvatljiva sol izabrana iz skupine koja se sastoji od hidroklorida, hidrobromida, hidrojodida, nitrata, sulfata, bisulfata, fosfata, kiselinskog fosfata, izonikotinata, acetata, laktata, salicilata, citrata, tartrata, pantotenata, bitartrata, askorbata, sukcinata, maleata, gentizinata, fumarata, glukonata, glukaronata, saharata, formata, benzoata, glutamata, metansulfonata, etansulfonata, benzensulfonata, p-toluensulfonata i pamoata.
a determination section that determines the amount of resource of the control information in each of the plurality of layers; and 
Terminalni uređaj (200) koji prenosi kontrolnu informaciju u pluralitetu slojeva, uređaj sadržeći:
Procedure according to claim 1) characterised by the fact that it provides a flexible joint in the joint holder, positioning the joint holder in the dig on the short side opposite the previously constructed panel and releasing the joint after the concrete has been cast and hardened. 
Metoda izrade sukladno zahtjevu 1, naznačena time da je fleksibilni zglob sadržanu u zglobnom držaču, postavljanjem zglobnog držača u iskop uz kraću stranu nasuprot prethodno izrađenom panelu i otpuštanjem zgloba nakon što se beton izlio i stvrdnuo. t>&
An additional crop (4.4 g., m.p. 190-191°C.) was obtained by evaporation of the mother liquors under vacuum to residues, followed by crystallization of the residues from boiling ethanol (150 ml.). 
Dopunski prinos (4.4 g., t.t. 190-191%C) dobiva se isparavanjem matičnih lugova u vakuumu do ostataka, 1 zatim kristalizacijom ostataka iz ključalog etanola (150 ml).
means phenyl-, benzyl-, thienyl-, or furyl group substituted with methylenedioxy group or with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, hydroxyl group, trifluoromethyl group, cyano group or halogen atom, or 
označuje fenilnu, benzilnu, tienilnu ili furilnu skupinu, supstituiranu s metilendioksi skupinom ili s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina, hidroksilnih skupina, trifluormetilnih skupina, cijano skupina ili atoma halogena, ili
In another aspect, the invention provides the use of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline (Form III) in the manufacture of a medicament for use in the treatment or prophylaxis of the above disorders. 
U daljnjem aspektu ovaj izum osigurava upotrebu 3-fenilsulfonil-8-piperazin-1-ilkinolina (Oblik III) u poroizvodnji lijeka namijenjenog upotrebi u liječenju ili profilaksi gore navedenih poremećaja.